Athira Pharma Analyst Ratings
Mizuho Downgrades Athira Pharma to Neutral, Lowers Price Target to $0.5
Mizuho Securities Downgrades Athira(ATHA.US) to Hold Rating, Cuts Target Price to $0.5
Jefferies Maintains Athira(ATHA.US) With Hold Rating, Cuts Target Price to $0.5
JMP Securities Maintains Athira(ATHA.US) With Hold Rating
Athira Pharma: A Cautious Hold Amid Strategic Pivot and Clinical Progress
Mizuho Securities Maintains Athira(ATHA.US) With Buy Rating, Announces Target Price $5
Athira Pharma Cut to Neutral From Buy by BTIG
Athira Pharma Analyst Ratings
Stifel Maintains Athira(ATHA.US) With Hold Rating, Maintains Target Price $4
JMP Securities Downgrades Athira(ATHA.US) to Hold Rating
BTIG Downgrades Athira(ATHA.US) to Hold Rating
BTIG Downgrades Athira Pharma (ATHA) to a Hold
Rodman & Renshaw Initiates Athira(ATHA.US) With Buy Rating, Announces Target Price $22
Athira Pharma Analyst Ratings
Rodman & Renshaw Initiates Athira Pharma at Buy With $22 Price Target
JMP Securities Maintains Athira(ATHA.US) With Buy Rating, Maintains Target Price $19
Buy Rating Affirmed for Athira Pharma Amid Positive LIFT-AD Trial Prospects and Expanding Pipeline
Mizuho Securities Keeps Their Buy Rating on Athira Pharma (ATHA)
Athira Pharma Analyst Ratings